190
Participants
Start Date
November 25, 2013
Primary Completion Date
April 19, 2016
Study Completion Date
March 14, 2017
V160 Low Dose IM
V160 administered as a 0.75 mL intramuscular injection
V160 Medium Dose IM
V160 administered as a 0.75 mL intramuscular injection
V160 High Dose IM
V160 administered as a 0.75 mL intramuscular injection
V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg /dose IM
V160 plus MAPA administered as a 0.75 mL intramuscular injection
V160 High Dose plus MAPA 225 µg /dose IM
V160 plus MAPA administered as a 0.75 mL intramuscular injection
V160 Maximum Dose IM
V160 administered as a 0.75 mL intramuscular injection
Placebo IM
Placebo administered as a 0.75 mL intramuscular injection
V160 Medium Dose ID
V160 administered as a 0.1 mL intradermal injection
Placebo ID
Placebo administered as a 0.1 mL intradermal injection
Merck Sharp & Dohme LLC
INDUSTRY